Novo Nordisk open to direct New York listing, CEO says

Health Pharma & Biotech Written by: Ian Lyall 12:12 Wed 23 Sep 2026 --> Disclaimer No investment advice About this content Editorial Standards & Policies Share article About this content × About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business output at the Daily... Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. Use of technology Proactive has always been a forward looking and enthusiastic technology adopter. Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows. Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation. Novo Nordisk ( NYSE:NVO ) View Price & Profile Novo Nordisk open to direct New York listing, CEO says Published: 12:12 23 Sep 2026 EDT Novo Nordisk (NYSE:NVO) ( NYSE:NVO ), the Danish drugmaker, would be open to considering a direct listing of its shares on the New York Stock Exchange, according to chief executive Mike Doustdar. Doustdar told the Financial Times that he could see advantages to such a move, although he clarified that the Danish pharmaceutical company is not currently exploring a change to its US listing structure. For now, Novo Nordisk (NYSE:NVO) is not actively exploring a direct US listing, leaving any potential NYSE listing as a future option rather than an active initiative. Novo Nordisk currently has its primary listing on Nasdaq Copenhagen, while US investors can trade the company’s American depositary receipts (ADRs) in New York. A direct listing would replace the ADR structure and give US investors direct access to Novo Nordisk shares through the NYSE. Doustdar’s comments come as Novo Nordisk maintains its existing presence in the US market through its American depositary receipt program, without actively pursuing a change in its listing structure. The potential move would change how US investors access Novo Nordisk shares, rather than alter the company’s underlying business or operations. Novo Nordisk shares fell over 2% on Wednesday after Doustdar's interview. The pharma company held a capital markets day on Monday, outlining plans to diversify its portfolio and strengthen its pipeline as it targets more than five multi-blockbuster launches by 2030. Continue reading